BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

Summary

BioMarin Pharmaceutical and n-Lorem Foundation have entered into an early-stage research collaboration to develop a potential first-in-disease medicine for ReNU Syndrome. The partnership represents routine early-stage collaboration for potential rare disease treatment development.